Balloon-Expandable Valve Outdoes Itself

The objective of this paper recently published in J Am Coll Cardiol Intv was to compare the outcomes of transcatheter aortic valve replacement (TAVR) with the new Sapien 3 Ultra vs. Sapien 3.

La válvula balón expandible se supera a sí misma

Successful implantation was extremely high with both balloon-expandable devices, which also had a very low adverse event rates. However, Sapien Ultra was significantly better than Sapien 3 in terms of paravalvular leak.

Both valves are made of bovine pericardium, with a cobalt-chromium stent plus a low-profile delivery system and high radial force. Sapien Ultra additionally has a polyethylene external skirt, which increases the device height by 40%, providing a 50% bigger contact surface with the native valve so as to improve annular sealing. The release system features differences too.

This registry included all consecutive patients who underwent TAVR with Sapien 3 and Sapien Ultra between 2014 and 2020. Propensity score matching was used to compare both arms.

A total of 310 matched patients were included (155 for each device). After propensity score matching, no difference was detected in baseline clinic characteristics.


Read also: Low-Carb Diet and Coronary Artery Calcium Progression.


Procedures were more frequently done under conscious sedation with Sapien Ultra (97.4% vs. 71.6%; p < 0.001) and pre-dilation was significantly less (42.6% vs. 85.2%; p < 0.001).

In-hospital results, including implantation success (91.6% vs. 95.5%; p = 0.165), major vascular complications (12.3% vs. 11.0%; p = 0.723), and pacemaker implantation (5.8% vs. 4.5%; = 0.608) were comparable between Sapien 3 and Ultra, respectively. 

The postprocedural gradient was similar (13.2 ± 5.7 mmHg vs. 13.1 ± 4.7 mmHg; = 0.829) and so were the rates for moderate and higher paravalvular leak (1.3% vs. 2.7%; p = 0.414).


Read also: AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation.


The significant difference in favor of Sapien Ultra was in mild leak with a rate that was less than half the rate for Sapien 3 (18.7% vs. 43%; p < 0.001).

Conclusion

With excellent results in both devices, adding a polyethylene skirt in the Sapien Ultra device managed to reduce the rate of mild paravalvular leak to less than half.

j-jcin-2020-07-013

Original Title: Transcatheter Aortic Valve Replacement With Balloon-Expandable Valves Comparison of SAPIEN 3 Ultra Versus SAPIEN 3.

Reference: Tobias Rheude et al. J Am Coll Cardiol Intv 2020;13:2631–8. https://doi.org/10.1016/j.jcin.2020.07.013.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...